Browsing: Alzheimer’s Disease

Brain Bank Singapore, Southeast Asia’s first brain bank, has gained 380 pledges to advance research on Alzheimer’s, Parkinson’s, and mental health disorders. This vital work focuses on understanding neurological conditions within Asian populations.

Eli Lilly gains approval for their Alzheimer’s drug donanemab (Kisunla) in Japan, offering another treatment targeting amyloid plaques like Eisai’s Leqembi as the ageing population drives a rise in dementia cases.

For most Singaporeans, medical insurance is their primary protection from sickness. It shields them both financially and medically. A core component of medical insurance is critical illness.  In this article, guest writer Michael Seow gives a clearer understanding of what critical illness coverage provides.

Revolutionising Alzheimer’s Diagnosis: Pioneering Blood Test Detects Disease Earlier Than Ever In a significant stride towards advancing Alzheimer’s disease diagnostics,…

Eli Lilly’s Alzheimer’s medication donanemab shows significant potential in slowing cognitive decline. Find out more

Dementia is a syndrome characterised by the deterioration in memory, thinking, behaviour, and the ability to perform everyday activities. It…

Alzheimer’s disease (AD) is a degenerative disorder of the brain, characterised commonly by progressive memory loss, cognitive deficit (reduced mental…